Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 8
Submit an article Journal homepage
1,316
Views
0
CrossRef citations to date
0
Altmetric
Author's View

Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target

Muhammad Zaeem NomanLaboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg
,
Jerome PaggettiLaboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg
,
Etienne MoussayLaboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg
,
Guy BerchemLaboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg;Centre Hospitalier du Luxembourg, Service d'Hemato-Oncologie, Luxembourg City, Luxembourg
&
Bassam JanjiLaboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, LuxembourgCorrespondence[email protected]
Article: e1452583 | Received 08 Mar 2018, Accepted 10 Mar 2018, Published online: 25 Apr 2018

References

  • Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L, Vitale M. NK cells and cancer. J Immunol. 2007;178:4011–6. doi:10.4049/jimmunol.178.7.4011. PMID:17371953.
  • Carotta S. Targeting NK cells for anticancer immunotherapy: Clinical and preclinical approaches. Front Immunol. 2016;7:152. doi:10.3389/fimmu.2016.00152. PMID:27148271.
  • Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 2014;4:522–6. doi:10.1158/2159-8290.CD-13-0985. PMID:24795012.
  • Galluzzi L, Bravo-San Pedro JM, Levine B, Green DR, Kroemer G. Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat Rev Drug Discov. 2017;16:487–511. doi:10.1038/nrd.2017.22. PMID:28529316.
  • Mgrditchian T, Arakelian T, Paggetti J, Noman MZ, Viry E, Moussay E, Van Moer K, Kreis S, Guerin C, Buart S, et al. Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. Proc Natl Acad Sci U S A. 2017;114:E9271–E9. doi:10.1073/pnas.1703921114. PMID:29078276.
  • Bakker AB, Phillips JH, Figdor CG, Lanier LL. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J Immunol. 1998;160:5239–45. PMID:9605119.
  • Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr, Blaser BW, et al. Preclinical characterization of 1–7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114:2667–77. doi:10.1182/blood-2009-02-206532. PMID:19553639.
  • Childs RW, Carlsten M. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov. 2015;14:487–98. doi:10.1038/nrd4506. PMID:26000725.
  • Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7:97–106. doi:10.1177/1758834014567469. PMID:25755682.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.